EyePoint Pharmaceuticals will launch both Dexycu and Yutiq in the first quarter, the company announced in a press release.
The two drugs were approved in 2018, and while the company originally planned to launch Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) in the first quarter of 2019 and Dexycu (dexamethasone intraocular suspension 9%) in the first half of the year, it has moved its timeline forward to launch both in the year’s first few months.
“EyePoint has made significant progress in building its commercial infrastructure in preparation for two ophthalmic product
Uncategorized